A Member of the University of Maryland Medical System | In Partnership with the University of Maryland School of Medicine
While medications play an essential role in the management of asthma, appropriate management of asthma involves much more:
The severity of asthma is classified into four groups: Intermittent, Mild Persistent, Moderate Persistent, and Severe Persistent. Six specific components of severity are used to classify patients. These components are:
Patients can greatly reduce the frequency and severity of asthma attacks by understanding the difference between coping with asthma attacks and controlling the disease over time.
Medications for asthma fall into two categories:
Patients can greatly reduce the frequency and severity of asthma attacks by understanding the difference between coping with asthma attacks and controlling the disease over time. Unfortunately, many patients do not understand the difference between medications that provide rapid short-term relief and those that are used for long-term symptom control. Many patients with moderate or severe asthma overuse their short-term medications and underuse their corticosteroid medications. The overuse of bronchodilators can have serious consequences; not using steroids can lead to permanent lung damage.
These are the signs of well-controlled asthma:
A stepwise approach is recommended for treating asthma. Medications and dosages are increased when needed, and decreased when possible. Based on severity of patients' asthma and their age, there are specific recommendations regarding whether to use long-term control medications and which ones to use. Patient education, environmental control measures, and management of any other conditions are also included. Doctors may always adjust these recommendations based on a specific patient.
In choosing therapy, doctors must also consider the risk an individual patient has for more severe exacerbations. Factors that may contribute to this include parental history of asthma, atopic dermatitis, and known sensitivity to different allergens or foods. Patients should be reevaluated within 2 - 6 weeks to assess response.
Key points regarding recommendations for adults include:
Most asthma drugs are taken with inhalers. In a hospital setting, or when a patient cannot use an inhaler, a nebulizer may be used. A nebulizer is a device that administers the drug in a fine spray that the patient breathes in. The two basic inhaler devices are the metered-dose inhaler (MDI) and dry powder inhalers (DPIs).
Metered-Dose Inhaler. The standard device for administering any asthma medication is the metered-dose inhaler (MDI). This device allows precise doses to be delivered directly to the lungs. They vary, however, in their ability to deliver medication. Often MDIs continue to deliver propellant after the drug has been used up. Patients should track their medicine and throw the device away when the last dose has been administered.
MDI-delivered drugs must be used regularly as prescribed, and the patient carefully trained in their use, for the drugs to be effective and safe. Some patients hold the MDI too close to their mouths, or even inside them. Others may exhale too forcefully before inhalation. A spacer, which is short tube attached to the mouthpiece, can help patients make sure they are getting the right amount of medication.
Dry Powder Inhalers. Dry powder inhalers (DPIs) deliver a powdered form of beta2-agonists or corticosteroids directly into the lungs. Some patients find that they are easier to manage than MDIs. Humidity or extreme temperatures can affect the performance of these inhalers, so they should not be stored in humid places (bathroom cabinets) or locations subject to high temperatures (glove compartments during summer months.
Dry-powder may cause tooth erosion, and children are advised to rinse their mouths out right after using a DPI and to brush twice a day with a fluoride toothpaste.
People who self-manage their asthma with peak air flow measurements and adjust their medications as needed have fewer hospitalizations and unplanned doctors visits, and, generally, have a better quality of life than those who rely only on the occasional doctor or emergency room visit to control symptoms. Doctors recommend that patients with even mild asthma monitor their own conditions.
In general, monitoring involves the following steps:
Guidelines from the National Asthma Education and Prevention Program (NAEPP) emphasize that most asthma medications are safe for pregnant women. The guidelines recommend that pregnant women with asthma have albuterol available at all times. Inhaled corticosteroids should be used for persistent asthma. Patients whose persistent asthma does not respond to standard dosages of inhaled corticosteroids may need a higher dosage or the addition of a long-acting beta-agonist to their drug regimen. For severe asthma, oral corticosteroids may be necessary. The NAEPP notes that while it is not clear if oral corticosteroids are safe for pregnant women, uncontrolled asthma poses an even greater risk for a woman and her fetus.
Medications for Treatment and Prevention of Asthma | ||||
| Medication Purpose | Drug Class | Generic Name | Brand Names | Administration |
| Quick-Relief (Rescue) Medications (control acute attacks) | Short-Acting Beta2-Agonists | Albuterol | Proventil, Ventolin, AccuNeb | Inhaler, nebulizer |
| Levalbuterol | Xopenex | Nebulizer | ||
| Metaproterenol | Alupent | Inhaler | ||
| Pirbuterol | MaxAir | Inhaler | ||
| Ipratropium/Albuterol | Combivent | Inhaler | ||
| Anticholinergics | Ipratropium | Atrovent | Inhaler | |
| Tiotropium | Spiriva | Inhaler | ||
| Systemic Corticosteroids | Cortisone | Cortone | Pill | |
| Dexamethasone | Decadron | Pill | ||
| Hydrocortisone | Cortef | Pill | ||
| Methylprednisolone | Medrol | Pill | ||
| Prednisolone | Orapred, Prelone | Syrup | ||
| Prednisone | Various | Pill | ||
| Triamcinolone | Aristocort | Pill | ||
| Long-Term Relief (Controller) Medications (prevent attacks and control chronic symptoms) | Inhaled Corticosteroids | Beclomethasone | QVAR | Inhaler |
| Budesonide | Pulmicort | Inhaler, nebulizer | ||
| Budesonide/Formoterol | Symbicort | Inhaler | ||
| Ciclesonide | Alvesco | Inhaler | ||
| Flunisolide | AeroBid | Inhaler | ||
| Fluticasone | Flovent | Inhaler | ||
| Fluticasone/Salmeterol | Advair | Inhaler | ||
| Mometasone | Asmanex | Inhaler | ||
| Triamcinolone | Azmacort | Inhaler | ||
| Long-Acting Beta2-Agonists | Formoterol | Foradil | Inhaler | |
| Note: In 2008, FDA advisory panel voted to ban Foradil and Serevent. | Salmeterol | Serevent | Inhaler | |
| Anti-inflammatories | Cromolyn | Intal | Nebulizer | |
| IgE-inhibitor | Omalizumab | Xolair | Injectable | |
| Leukotriene Modifiers | Montelukast | Singulair | Pill | |
| Zafirlukast | Accolate | Pill | ||
| Methylxanthine | Theophylline | Uniphyl, Quibron, Theo-24 | Pill, syrup | |
American Lung Association. Trends in asthma morbidity and mortality. American Lung Association Epidemiology & Statistics Unit Research and Program Services. November 2007.
Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, Yancey S. Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med. 2008 Jul 1;149(1):33-42. Epub 2008 Jun 3.
Fanta CH. Asthma. N Engl J Med. 2009 Mar 5;360(10):1002-14.
Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al. Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2007 Jan;119(1):192-8. Epub 2006 Oct 23.
National Asthma Education and Prevention Program Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics -- 2002. Rockville, MD. National Heart, Lung, and Blood Institute, US Dept of Health and Human Services; 2003. NIH publications 02-5074.
National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Rockville, MD. National Heart, Lung, and Blood Institute, US Dept of Health and Human Services; 2007. NIH publications 08-4051.
Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW. Corticosteroids for preventing relapse following acute exacerbations of asthma. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD000195.
Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006 Jun 20;144(12):904-12.
Schatz M, Dombrowski MP. Clinical practice. Asthma in pregnancy. N Engl J Med. 2009 Apr 30;360(18):1862-9.
Slavin RG, Haselkorn T, Lee JH, Zheng B, Deniz Y, Wenzel SE; TENOR Study Group. Asthma in older adults: observations from the epidemiology and natural history of asthma: outcomes and treatment regimens (TENOR) study. Ann Allergy Asthma Immunol. 2006 Mar;96(3):406-14.
Vliagoftis H, Kouranos VD, Betsi GI, Falagas ME. Probiotics for the treatment of allergic rhinitis and asthma: systematic review of randomized controlled trials. Ann Allergy Asthma Immunol. 2008 Dec;101(6):570-9.
A.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).
© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885